|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
phenethylamine binds to and results in decreased activity of ADRA1A protein |
CTD |
PMID:20217639 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
affects binding |
ISO |
phenethylamine binds to ADRA2A protein |
CTD |
PMID:20217639 |
|
NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
affects binding |
ISO |
phenethylamine binds to ADRA2C protein |
CTD |
PMID:20217639 |
|
NCBI chr14:80,730,307...80,732,010
Ensembl chr14:80,730,307...80,732,010
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions |
ISO |
Phenylpropanolamine inhibits the reaction [MAOB protein results in increased degradation of phenethylamine] |
CTD |
PMID:3961266 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Slc18a1 |
solute carrier family 18 member A1 |
multiple interactions |
ISO |
phenethylamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] |
CTD |
PMID:8245983 |
|
NCBI chr16:22,358,646...22,395,183
Ensembl chr16:22,361,998...22,395,183
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
SLC6A2 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions increases transport |
ISO |
Cocaine inhibits the reaction [SLC6A3 protein results in increased transport of phenethylamine]; SLC6A3 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:15764732 PMID:17234900 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
ISO |
SLC6A4 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions increases activity |
ISO |
[phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; SLC6A2 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 PMID:19725810 |
|
NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
|
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
increases activity multiple interactions |
ISO |
O-methyltyramine results in increased activity of TAAR1 protein [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
4-phenylbutylamine results in increased expression of ABCC4 mRNA; 4-phenylbutylamine results in increased expression of ABCC4 protein |
CTD |
PMID:20395535 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of BBC3 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
4-phenylbutylamine promotes the reaction [Zearalenone results in increased expression of DDIT3 protein] |
CTD |
PMID:30394307 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
multiple interactions |
ISO |
4-phenylbutylamine promotes the reaction [Zearalenone results in increased expression of HERPUD1 protein] |
CTD |
PMID:30394307 |
|
NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
4-phenylbutylamine promotes the reaction [Zearalenone results in increased expression of HSPA5 protein] |
CTD |
PMID:30394307 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of TRIB3 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
benzylamine binds to and results in increased activity of AHR protein |
CTD |
PMID:11790108 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
|
G |
Gusb |
glucuronidase, beta |
increases secretion |
EXP |
p-Methoxy-N-methylphenethylamine results in increased secretion of GUSB protein |
CTD |
PMID:9545557 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases activity |
EXP |
p-Methoxy-N-methylphenethylamine results in increased activity of HTR1A protein |
CTD |
PMID:16415902 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Kng2 |
kininogen 2 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of KNG1 protein |
CTD |
PMID:1371395 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions increases activity |
EXP |
atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein] |
CTD |
PMID:27553716 |
|
NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29402411 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29402411 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of NR3C1 protein |
CTD |
PMID:7887964 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
|
G |
Dek |
DEK proto-oncogene |
increases secretion |
ISO |
DEK protein results in increased secretion of dimethylamine |
CTD |
PMID:28558019 |
|
NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
ISO EXP |
dimethylamine binds to and results in decreased activity of HRH3 protein |
CTD |
PMID:17169555 |
|
NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395
|
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects binding multiple interactions |
ISO |
CHRM1 protein binds to furtrethonium brucine promotes the reaction [furtrethonium binds to CHRM1 protein] |
CTD |
PMID:9224827 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
affects binding multiple interactions |
ISO |
CHRM2 protein binds to furtrethonium eburnamonine promotes the reaction [furtrethonium binds to CHRM2 protein] |
CTD |
PMID:9224827 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions affects binding |
ISO |
brucine promotes the reaction [furtrethonium binds to CHRM3 protein] CHRM3 protein binds to furtrethonium |
CTD |
PMID:9224827 |
|
NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions affects binding |
ISO |
brucine promotes the reaction [furtrethonium binds to CHRM4 protein] CHRM4 protein binds to furtrethonium |
CTD |
PMID:9224827 |
|
NCBI chr 3:80,833,272...80,841,165
Ensembl chr 3:80,833,272...80,841,006
|
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
decreases amination multiple interactions |
ISO |
AOC3 protein results in decreased amination of methylamine mofegiline inhibits the reaction [AOC3 protein results in decreased amination of methylamine] |
CTD |
PMID:15128865 |
|
NCBI chr10:89,251,370...89,259,313
Ensembl chr10:89,251,370...89,259,313
|
|
G |
Ifnar1 |
interferon alpha and beta receptor subunit 1 |
multiple interactions |
ISO |
methylamine inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IFNAR1 protein] |
CTD |
PMID:18722370 |
|
NCBI chr11:31,640,407...31,666,839
Ensembl chr11:31,640,407...31,664,061
|
|
G |
Kcna6 |
potassium voltage-gated channel subfamily A member 6 |
affects response to substance |
ISO |
KCNA6 protein affects the susceptibility to methylamine |
CTD |
PMID:15100162 |
|
NCBI chr 4:159,253,934...159,287,193
Ensembl chr 4:159,253,934...159,287,193
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
methylamine inhibits the reaction [Botulinum Toxins, Type A results in increased cleavage of SNAP25 protein] |
CTD |
PMID:11181932 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
Methylamines analog results in decreased activity of CA1 protein |
CTD |
PMID:29457667 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
Methylamines analog results in decreased activity of CA2 protein |
CTD |
PMID:29457667 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
|
G |
Gusb |
glucuronidase, beta |
increases secretion |
EXP |
p-Methoxy-N-methylphenethylamine results in increased secretion of GUSB protein |
CTD |
PMID:9545557 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases activity |
EXP |
p-Methoxy-N-methylphenethylamine results in increased activity of HTR1A protein |
CTD |
PMID:16415902 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Kng2 |
kininogen 2 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of KNG1 protein |
CTD |
PMID:1371395 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions increases activity |
EXP |
atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein] |
CTD |
PMID:27553716 |
|
NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29402411 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29402411 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases activity |
ISO |
p-Methoxy-N-methylphenethylamine results in decreased activity of NR3C1 protein |
CTD |
PMID:7887964 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
affects response to substance |
ISO |
AKT2 protein affects the susceptibility to N-(3-(aminomethyl)benzyl)acetamidine |
CTD |
PMID:21964073 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:19442826 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxygen deficiency results in increased expression of CAV1 protein] |
CTD |
PMID:18717816 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] |
CTD |
PMID:15542068 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein] |
CTD |
PMID:15542068 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Phenytoin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:18206661 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein] |
CTD |
PMID:21397656 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] |
CTD |
PMID:11076874 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] |
CTD |
PMID:11076874 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP1A protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP2A protein] |
CTD |
PMID:16963453 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Lepr |
leptin receptor |
increases response to substance |
EXP |
LEPR gene mutant form results in increased susceptibility to N-(3-(aminomethyl)benzyl)acetamidine |
CTD |
PMID:30689673 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:11504810 PMID:11713966 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity |
ISO EXP |
[N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [fluvastatin results in increased abundance of Nitric Oxide]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] which results in increased susceptibility to endothelium-dependent hyperpolarization factor; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Potassium Cyanide results in increased expression of NOS2 protein] [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased chemical synthesis of Reactive Oxygen Species]; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:11076874 PMID:11134894 PMID:16461118 PMID:16933320 PMID:19442826 PMID:19951519 PMID:20035746 PMID:20497644 PMID:20549418 PMID:23061969 PMID:24964743 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP1A protein] |
CTD |
PMID:16963453 |
|
NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
|
|
G |
Rap2a |
RAP2A, member of RAS oncogene family |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [ITGB2 protein results in increased activity of RAP2A protein] |
CTD |
PMID:16963453 |
|
NCBI chr15:105,851,543...105,852,033
Ensembl chr15:105,851,542...105,878,666
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [GGTI 298 results in decreased expression of TFRC protein] |
CTD |
PMID:24964743 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein] |
CTD |
PMID:11076874 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO EXP |
Ranitidine binds to and results in decreased activity of ACHE protein; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] Ranitidine affects the reaction [Paraoxon results in decreased activity of ACHE protein] |
CTD |
PMID:15669026 PMID:15669039 PMID:16193528 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ACKR3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ADAMTS1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[Ranitidine co-treated with Diclofenac] results in decreased expression of ALB protein; Quercetin inhibits the reaction [[Ranitidine co-treated with Diclofenac] results in decreased expression of ALB protein] |
CTD |
PMID:28400101 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ALDOA mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Amotl2 |
angiomotin like 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of AMOTL2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 8:111,210,261...111,226,217
Ensembl chr 8:111,209,908...111,226,226
|
|
G |
Arhgef11 |
Rho guanine nucleotide exchange factor 11 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ARHGEF11 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:186,979,850...187,102,523
Ensembl chr 2:186,980,793...187,101,768
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATF3 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ATF3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA]; Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ATP1B1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Rotenone results in increased expression of BAX protein] Ranitidine inhibits the reaction [Aspirin results in increased expression of BAX protein] |
CTD |
PMID:19723537 PMID:30885738 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
Ranitidine binds to and results in decreased activity of BCHE protein; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein] |
CTD |
PMID:15669026 PMID:16193528 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] |
CTD |
PMID:19723537 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BHLHE40 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of BMP2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BTG2 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BTG2 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression |
ISO |
Ranitidine results in increased expression of CALCA protein |
CTD |
PMID:12495560 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of and results in increased activity of CASP3 protein] Ranitidine inhibits the reaction [Aspirin results in increased expression of CASP3 mRNA]; Ranitidine inhibits the reaction [Aspirin results in increased expression of CASP3 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of CASP3 mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of CASP3 protein] |
CTD |
PMID:19723537 PMID:28648817 PMID:29523851 PMID:30885738 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of CASP9 protein] |
CTD |
PMID:19723537 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Ranitidine inhibits the reaction [Indomethacin results in increased activity of CAT protein] |
CTD |
PMID:16169175 PMID:16397915 PMID:17895592 PMID:18087811 PMID:18726076 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnl1 |
cyclin L1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CCNL1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:157,747,295...157,759,838
Ensembl chr 2:157,747,542...157,759,838
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]] |
CTD |
PMID:12538815 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of CDK6 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CREM mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CTSL mRNA |
CTD |
PMID:16415329 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
EXP |
Ranitidine results in decreased expression of CXCL1 protein |
CTD |
PMID:12023551 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA; [Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]]; Pentoxifylline inhibits the reaction [[Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein] |
CTD |
PMID:16401727 PMID:16415329 PMID:17698507 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of DDAH1 mRNA] |
CTD |
PMID:29523851 |
|
NCBI chr 2:251,634,368...251,766,009
Ensembl chr 2:251,634,431...251,766,014
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of DDIT4 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of DIO3 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of DUSP1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of EFNA1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Egfl7 |
EGF-like-domain, multiple 7 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of EGFL7 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 3:4,034,759...4,044,280
Ensembl chr 3:4,034,921...4,043,936
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] |
CTD |
PMID:29523851 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 6:75,050,329...75,075,795
Ensembl chr 6:75,050,329...75,075,795
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGR1 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of EGR1 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of F3 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FGF23 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
affects metabolic processing |
ISO |
FMO3 protein affects the metabolism of Ranitidine |
CTD |
PMID:15286053 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FOS mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of FOSL2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:25,598,936...25,616,995
Ensembl chr 6:25,598,936...25,616,995
|
|
G |
Foxq1 |
forkhead box Q1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FOXQ1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr17:34,224,308...34,226,941
Ensembl chr17:34,224,818...34,226,453
|
|
G |
Fst |
follistatin |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of FST mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of FST mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GADD45A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gast |
gastrin |
affects expression multiple interactions |
ISO EXP |
Ranitidine affects the expression of GAST protein Ranitidine inhibits the reaction [GAST protein modified form results in increased secretion of Acids] |
CTD |
PMID:2470453 PMID:12503773 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GOT1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
Hist3h2a |
histone cluster 3, H2a |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of H2A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:45,297,603...45,299,155
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of HNF4A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HOMER1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:22,909,550...23,012,303
Ensembl chr 2:22,909,569...23,009,678
|
|
G |
Hoxa5 |
homeo box A5 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HOXA5 mRNA |
CTD |
PMID:16415329 |
|
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions decreases activity |
ISO EXP |
[Ranitidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; Ranitidine binds to and results in decreased activity of HRH2 protein; Ranitidine inhibits the reaction [tiotidine binds to HRH2 protein] Ranitidine results in decreased activity of HRH2 protein Ranitidine binds to and results in decreased activity of HRH2 protein; Ranitidine inhibits the reaction [Dimaprit binds to and results in increased activity of HRH2 protein]; Ranitidine inhibits the reaction [Melitten results in increased activity of HRH2 protein] |
CTD |
PMID:6106871 PMID:6835285 PMID:7512805 PMID:9681472 PMID:9819373 PMID:11527950 PMID:12100006 PMID:14671421 PMID:16143415 PMID:16632449 PMID:22995146 |
|
NCBI chr17:10,912,959...10,931,389
Ensembl chr17:10,921,507...10,952,441
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of HSPA1A mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of HSPB8 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]] |
CTD |
PMID:11752121 PMID:12538815 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ID2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Id4 |
inhibitor of DNA binding 4, HLH protein |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ID4 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:16,692,557...16,695,126
Ensembl chr17:16,692,557...16,695,126
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]] [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:10569698 PMID:11752121 PMID:16415329 PMID:17698507 PMID:19362101 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IFRD1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 6:60,132,025...60,151,354
Ensembl chr 6:60,132,024...60,151,420
|
|
G |
Igsf10 |
immunoglobulin superfamily, member 10 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IGSF10 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 2:149,535,199...149,564,180
Ensembl chr 2:149,533,151...149,564,113
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP ISO |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]] |
CTD |
PMID:11752121 PMID:17698507 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine results in decreased expression of IL12A protein] |
CTD |
PMID:9819373 PMID:11752121 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine results in decreased expression of IL12B protein] |
CTD |
PMID:9819373 PMID:11752121 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]] |
CTD |
PMID:11752121 PMID:16723495 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine |
CTD |
PMID:19362101 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
Ranitidine results in increased expression of IL1B protein Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of IL1B protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:15265675 PMID:17698507 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL4 protein] |
CTD |
PMID:29523851 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of IL6 mRNA]; Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of IL6 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of IL6 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:15265675 PMID:16401727 PMID:16415329 PMID:17698507 PMID:28648817 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inhbe |
inhibin subunit beta E |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of INHBE mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of INSIG1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Insig2 |
insulin induced gene 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of INSIG2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:37,264,818...37,292,718
Ensembl chr13:37,266,312...37,287,458
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of IRS2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr16:83,824,515...83,848,569
Ensembl chr16:83,824,430...83,848,684
|
|
G |
Itpkc |
inositol-trisphosphate 3-kinase C |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ITPKC mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:84,018,857...84,040,433
Ensembl chr 1:84,018,859...84,040,433
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of JUN mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of KLF4 mRNA] |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of KLF6 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19723537 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19723537 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
multiple interactions increases expression |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of MAPKAPK2 mRNA Ranitidine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:16401727 PMID:16415329 |
|
NCBI chr13:47,785,157...47,871,684
Ensembl chr13:47,785,161...47,831,110
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Ethanol results in increased secretion of and results in increased activity of MMP9 protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of MMP9 protein] |
CTD |
PMID:17603938 PMID:29523851 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression |
EXP |
Ranitidine inhibits the reaction [Aspirin results in increased expression of MPO protein]; Ranitidine inhibits the reaction [Indomethacin results in increased activity of MPO protein] Ranitidine results in decreased expression of MPO protein |
CTD |
PMID:12023551 PMID:16169175 PMID:17895592 PMID:18726076 PMID:28648817 PMID:30885738 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of MYC mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NEDD4L mRNA |
CTD |
PMID:16415329 |
|
NCBI chr18:60,392,376...60,719,720
Ensembl chr18:60,392,376...60,719,720
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:28648817 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Capsaicin results in increased expression of NGF protein] |
CTD |
PMID:15265675 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Noct |
nocturnin |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NOCT mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:140,286,661...140,306,869
Ensembl chr 2:140,286,661...140,306,869
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:16169175 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NR4A1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of NUPR1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of P4HA1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:28,920,616...28,972,576
Ensembl chr20:28,920,616...28,971,966
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:19723537 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pfkl |
phosphofructokinase, liver type |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PFKL mRNA |
CTD |
PMID:16415329 |
|
NCBI chr20:11,393,860...11,415,889
Ensembl chr20:11,393,877...11,415,882
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PPP1R15A mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Preb |
prolactin regulatory element binding |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of PREB mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:26,784,088...26,787,875
Ensembl chr 6:26,784,088...26,787,874
|
|
G |
Prl |
prolactin |
affects expression increases secretion |
ISO |
Ranitidine affects the expression of PRL protein Ranitidine results in increased secretion of PRL protein |
CTD |
PMID:7878608 PMID:9037573 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of PTGS2 mRNA]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16401727 PMID:16415329 PMID:29523851 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pvr |
PVR cell adhesion molecule |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of PVR mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:80,820,306...80,835,712
Ensembl chr 1:80,820,050...80,835,701
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of RAC1 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Ranitidine inhibits the reaction [Indomethacin results in increased expression of RELA protein] |
CTD |
PMID:28648817 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ren |
renin |
affects activity |
ISO |
Ranitidine affects the activity of REN protein |
CTD |
PMID:1972605 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of RGS2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:60,846,458...60,849,061
Ensembl chr13:60,846,308...60,849,094
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of RGS4 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr13:88,054,817...88,061,108
Ensembl chr13:88,054,817...88,061,108
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ARHB mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SERPINE1 mRNA; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Pentoxifylline inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein] |
CTD |
PMID:16401727 PMID:16415329 PMID:17698507 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sh2b2 |
SH2B adaptor protein 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of APS mRNA |
CTD |
PMID:16415329 |
|
NCBI chr12:23,471,477...23,501,043
Ensembl chr12:23,473,270...23,501,036
|
|
G |
Shank3 |
SH3 and multiple ankyrin repeat domains 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of SHANK3 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 7:130,474,278...130,534,679
Ensembl chr 7:130,474,279...130,534,679
|
|
G |
Sik1 |
salt-inducible kinase 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SIK1 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SIK1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr20:10,670,747...10,680,279
Ensembl chr20:10,668,411...10,680,283
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:97,733,701...97,758,723
Ensembl chr10:97,735,548...97,756,521
|
|
G |
Slc20a1 |
solute carrier family 20 member 1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC20A1 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 3:121,725,204...121,739,160
Ensembl chr 3:121,725,859...121,739,173
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions increases uptake affects transport |
ISO EXP |
Ranitidine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein results in increased uptake of Ranitidine SLC22A1 protein affects the transport of Ranitidine |
CTD |
PMID:16006492 PMID:16141367 PMID:16263091 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases uptake multiple interactions |
ISO EXP |
SLC22A2 protein results in increased uptake of Ranitidine Ranitidine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16006492 PMID:16141367 PMID:16263091 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [SLC22A3 protein affects the transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Ranitidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16141367 PMID:16263091 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases uptake |
ISO |
SLC22A6 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 |
|
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases uptake |
ISO |
SLC22A7 protein results in increased uptake of Ranitidine |
CTD |
PMID:16006492 |
|
NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases uptake multiple interactions |
ISO EXP |
SLC22A8 protein results in increased uptake of Ranitidine Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Ranitidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine] |
CTD |
PMID:15319347 PMID:16006492 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SLC2A1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Ranitidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
G |
Slc5a3 |
solute carrier family 5 member 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLC5A3 mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr11:32,229,366...32,231,812
|
|
G |
Slk |
STE20-like kinase |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of SLK mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr 1:267,359,761...267,415,735
Ensembl chr 1:267,359,830...267,412,810
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of SPHK1 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
ISO |
Ranitidine results in increased expression of TAC1 protein |
CTD |
PMID:12495560 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TFRC mRNA] |
CTD |
PMID:16401727 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Ranitidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Ranitidine; Ranitidine inhibits the reaction [Aspirin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Capsaicin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Indomethacin results in increased expression of TNF protein]; Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:11752121 PMID:12023551 PMID:12538815 PMID:15265675 PMID:17698507 PMID:19362101 PMID:28648817 PMID:29523851 PMID:30885738 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNFAIP6 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of TNFRSF12A mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr10:12,995,904...12,997,930
Ensembl chr10:12,995,904...12,997,930
|
|
G |
Tpm3 |
tropomyosin 3 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TPM3 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
|
|
G |
Trak2 |
trafficking kinesin protein 2 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of TRAK2 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 9:65,698,706...65,763,351
Ensembl chr 9:65,698,712...65,763,273
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of UBE2B mRNA |
CTD |
PMID:16415329 |
|
NCBI chr10:37,439,947...37,454,867
Ensembl chr10:37,441,284...37,455,022
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of VEGFA mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Zbtb10 |
zinc finger and BTB domain containing 10 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ZBTB10 mRNA |
CTD |
PMID:16415329 |
|
NCBI chr 2:94,692,939...94,730,976
Ensembl chr 2:94,692,939...94,730,978
|
|
G |
Zfyve27 |
zinc finger FYVE-type containing 27 |
multiple interactions |
EXP |
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ZFYVE27 mRNA] |
CTD |
PMID:16415329 |
|
NCBI chr 1:261,415,172...261,438,539
Ensembl chr 1:261,415,191...261,438,539
|
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
affects metabolic processing increases metabolic processing multiple interactions increases oxidation |
ISO EXP |
FMO3 gene polymorphism affects the metabolism of trimethylamine FMO3 protein results in increased metabolism of trimethylamine trimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole] FMO3 protein results in increased oxidation of trimethylamine FMO3 protein results in increased oxidation of trimethylamine; FMO3 results in increased oxidation of trimethylamine |
CTD |
PMID:11414682 PMID:12214664 PMID:16601883 PMID:17050781 PMID:17142560 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions increases chemical synthesis |
ISO |
[MTARC1 protein results in increased reduction of trimethyloxamine] which results in increased chemical synthesis of trimethylamine MTARC1 protein results in increased chemical synthesis of trimethylamine |
CTD |
PMID:29856598 |
|
NCBI chr13:102,693,679...102,724,120
Ensembl chr13:102,698,546...102,721,218
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of trimethylamine |
CTD |
PMID:21561886 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Taar5 |
trace amine-associated receptor 5 |
increases activity |
ISO |
trimethylamine results in increased activity of TAAR5 protein |
CTD |
PMID:23393561 |
|
NCBI chr 1:22,547,662...22,548,675
Ensembl chr 1:22,547,662...22,548,675
|
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of ATF4 protein] |
CTD |
PMID:25568320 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:25568320 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
trimethyloxamine inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of DDIT3 protein] |
CTD |
PMID:25568320 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
ISO |
trimethyloxamine promotes the reaction [MBP protein binds to MBP protein]; trimethyloxamine promotes the reaction [MBP protein mutant form binds to MBP protein mutant form] |
CTD |
PMID:12372316 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions increases reduction |
ISO |
[MTARC1 protein results in increased reduction of trimethyloxamine] which results in increased chemical synthesis of trimethylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] |
CTD |
PMID:29856598 |
|
NCBI chr13:102,693,679...102,724,120
Ensembl chr13:102,698,546...102,721,218
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects abundance |
ISO |
SLCO1A4 protein affects the abundance of trimethyloxamine |
CTD |
PMID:21561886 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
multiple interactions |
EXP |
trimethyloxamine promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form] |
CTD |
PMID:27032463 |
|
NCBI chr10:55,675,171...55,679,405
Ensembl chr10:55,675,575...55,679,450
|
|